Table 1.
Baseline characteristics of renal cell carcinoma patients (n = 114)
| Characteristics | N | % |
|---|---|---|
| Sex | ||
| male | 69 | 60.5 |
| female | 45 | 39.5 |
| Age | ||
| median (range) | 65.5 (45-88) | 47.4 |
| < 65 | 54 | 52.6 |
| > 65 | 60 | |
| ECOG | ||
| 0 | 83 | 72.8 |
| 1 | 28 | 24.6 |
| 2 | 3 | 2.6 |
| Nephrectomy | ||
| Yes | 108 | 94.7 |
| no | 6 | 5.3 |
| Time from primary to metastasis | ||
| < 1 year | 56 | 49.1 |
| > 1 year | 58 | 50.9 |
| Histology | ||
| clear cell | 104 | 91.2 |
| non clear cell | 10 | 8.8 |
| MSKCC | ||
| favourable | 45 | 39.5 |
| intermediate | 67 | 58.7 |
| poor | 2 | 1.8 |
| Number of metastasis | ||
| 1 | 32 | 28.1 |
| 2 | 54 | 47.4 |
| > 3 | 28 | 24.5 |
| Location of metastasis | ||
| Lung | 79 | 69.3 |
| Liver | 22 | 19.3 |
| Bone | 41 | 36 |
| Lymph nodes (LN) | 38 | 33.3 |
| CNS | 12 | 10.5 |
| other | 41 | 36 |
| Systemic therapy before first Targeted Agent (TA) | ||
| Cytokines | 54 | 47.4 |
| other | 11 | 9.6 |
| First targeted agent | ||
| Bevacizumab | 4 | 3.5 |
| Sunitinib | 72 | 63.2 |
| Sorafenib | 35 | 30.7 |
| Temsirolimus | 3 | 2.6 |